CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
1 - 13 . (canceled)
14 . A crystalline form of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one that has an X-ray powder diffraction (XRPD) pattern comprising 2-Theta peaks at about 7.0°, about 14.0°, and about 18.2°.
15 . The crystalline form of claim 14 , wherein the XRPD pattern further comprises a 2-Theta peak at about 15.7°.
16 . The crystalline form of claim 15 , wherein the XRPD pattern further comprises a 2-Theta peak at about 19.1°.
17 . The crystalline form of claim 16 , wherein the XRPD pattern further comprises a 2-Theta peak at about 19.5°.
18 . The crystalline form of claim 17 , wherein the XRPD pattern further comprises a 2-Theta peak at about 20.3°.
19 . The crystalline form of claim 18 , wherein the XRPD pattern further comprises a 2-Theta peak at about 22.10°.
20 . The crystalline form of claim 19 , wherein the XRPD pattern further comprises a 2-Theta peak at about 22.9°.
21 . The crystalline form of claim 14 , wherein the crystalline form is unsolvated.
22 . The crystalline form of claim 15 , wherein the crystalline form is unsolvated.
23 . The crystalline form of claim 16 , wherein the crystalline form is unsolvated.
24 . The crystalline form of claim 17 , wherein the crystalline form is unsolvated.
25 . The crystalline form of claim 18 , wherein the crystalline form is unsolvated.
26 . The crystalline form of claim 19 , wherein the crystalline form is unsolvated.
27 . The crystalline form of claim 20 , wherein the crystalline form is unsolvated.